Nature Communications (Aug 2021)
Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia
- Michela Consonni,
- Claudio Garavaglia,
- Andrea Grilli,
- Claudia de Lalla,
- Alessandra Mancino,
- Lucia Mori,
- Gennaro De Libero,
- Daniela Montagna,
- Monica Casucci,
- Marta Serafini,
- Chiara Bonini,
- Daniel Häussinger,
- Fabio Ciceri,
- Massimo Bernardi,
- Sara Mastaglio,
- Silvio Bicciato,
- Paolo Dellabona,
- Giulia Casorati
Affiliations
- Michela Consonni
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
- Claudio Garavaglia
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
- Andrea Grilli
- Department of Life Sciences, University of Modena and Reggio Emilia
- Claudia de Lalla
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
- Alessandra Mancino
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
- Lucia Mori
- Experimental Immunology, Department of Biomedicine, University of Basel and University Hospital
- Gennaro De Libero
- Experimental Immunology, Department of Biomedicine, University of Basel and University Hospital
- Daniela Montagna
- Foundation IRCCS Policlinico San Matteo; Department of Sciences Clinic-Surgical, Diagnostic and Pediatric, University of Pavia
- Monica Casucci
- Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
- Marta Serafini
- M. Tettamanti Research Center, University of Milano-Bicocca
- Chiara Bonini
- Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
- Daniel Häussinger
- NMR-Laboratory, Department of Chemistry, University of Basel
- Fabio Ciceri
- Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute
- Massimo Bernardi
- Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute
- Sara Mastaglio
- Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute
- Silvio Bicciato
- Department of Life Sciences, University of Modena and Reggio Emilia
- Paolo Dellabona
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
- Giulia Casorati
- Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
- DOI
- https://doi.org/10.1038/s41467-021-25223-0
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Leukaemia therapy may benefit from the use of antigens that are less restricted to individual donors. Here the authors engineered T cells with a TCR specific for a CD1c restricted lipid leukaemia antigen and show that they can protect against disease progression in mouse leukaemia xenograft models.
